NIH-funded research R01 grant

Understanding how a protein helps other proteins fold correctly

Official title: Determinants of the Hsp90-client interaction

Funded at University of Idaho · NIH-10458059 · Data updated 2026-11-12

This study is looking at a helper protein called Hsp90 to understand how it helps other proteins work properly, which could lead to better treatments for conditions like cancer and cystic fibrosis.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Idaho
NIH-funded
Lab location1 site (Moscow, United States)
Project startSeptember 16, 2019
Project endJuly 31, 2025
Funding year2022
Award (this year)$285,011
NIH project number5R01GM127675-04
Project IDNIH-10458059 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with cancer, cystic fibrosis, or other related diseases that involve protein misfolding.

Less likely to help

Patients with conditions unrelated to protein folding or those who do not have cancer or cystic fibrosis may not benefit from this research.

What this research studies

This research investigates the role of a molecular chaperone called Hsp90, which assists in the proper folding and functioning of various proteins in the body. By studying how Hsp90 interacts with its client proteins, the researchers aim to uncover the mechanisms that govern protein folding, which is crucial for cellular health. The project employs innovative techniques to manipulate Hsp90 and its associated proteins, potentially leading to the development of targeted therapies for diseases like cancer and cystic fibrosis. Patients may benefit from insights gained into how to improve treatment strategies for these conditions.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that specifically target and improve the function of proteins involved in cancer and cystic fibrosis.

How similar studies have gone: Other research has shown promising results in targeting molecular chaperones for therapeutic purposes, indicating that this approach has potential for success.

Where this research is happening

  • University of Idaho
    Moscow, United States
    Active

Researchers

  • Principal investigator: Johnson, Jill L — University of Idaho
  • Study coordinator: Johnson, Jill L

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.